Cardiac troponin T (cTnT) and troponin I are the biomarkers of choice in the evaluation of patients with acute coronary syndromes. Cardiac troponin has been independently associated with adverse outcomes after acute coronary syndrome, in patients with chronic heart failure, and in the general population, although cTnT levels are detectable in only a small fraction of the general population with the use of current assays. A precommercial highly sensitive cTnT assay can detect 10-fold lower concentrations than currently available assays. We sought to define the prevalence of measurable cTnT using this new highly sensitive assay and the associations of cTnT levels with adverse cardiovascular events in participants in the Atherosclerosis Risk in Communities (ARIC) Study, aged 54 to 74 years, who were initially free of cardiovascular disease. We found that the new highly sensitive cTnT assay detected circulating cTnT in 66.5% of the ARIC sample (Ͻ1% would have been detected by the currently available cTnT assays) and that measured cTnT had strong associations with coronary heart disease events, mortality, and heart failure and improved risk prediction. cTnT appears to be an important marker of coronary heart disease, mortality, and heart failure risk even in a healthy middle-aged population without manifest cardiovascular disease. See p 1367.
Cardiorespiratory Fitness and Classification of Risk of Cardiovascular Disease Mortality
Cardiorespiratory fitness has a well-documented inverse association with cardiovascular disease mortality independent of traditional risk factors. However, the extent to which fitness provides clinically meaningful risk information beyond traditional risk factors is unclear. In the present study, we assessed the contribution of fitness to traditional risk factors in cardiovascular disease risk classification using data from Ͼ66 000 asymptomatic individuals enrolled in the Cooper Center Longitudinal Study. During a median follow-up period of 16 years, there were 1621 cardiovascular disease deaths. We found that the addition of fitness to the traditional risk factor model resulted in significant net reclassification improvement at both 10 years and 25 years. These findings suggest that an assessment of fitness may have significant impact on risk prediction algorithms by providing a meaningful improvement in the identification of those individuals at risk for future cardiovascular disease mortality. In addition, these data might also be useful to practicing clinicians, facilitating more effective risk communication regarding the health benefits of fitness. See p 1377.
Do Postmarketing Surveillance Studies Represent Real-World Populations? A Comparison of Patient Characteristics and Outcomes After Carotid Artery Stenting From the National Cardiovascular Database Registry
Postmarketing surveillance studies (PMS) are commonly performed after the approval of cardiovascular devices and medications to evaluate the efficacy and safety of these therapies in real world practice, often at the request of the Food and Drug Administration.
However, few studies have examined whether patient characteristics and outcomes of PMS studies are truly representative of those treated in routine clinical practice. In this study from the National Cardiovascular Database Registry-Carotid Artery Revascularization and Endarterectomy (NCDR CARE) registry, the authors compared clinical characteristics and outcomes of patients undergoing carotid artery stenting (CAS) enrolled in postmarketing studies to those not enrolled in such studies. PMS study participants had overall less severe neurological disease histories, better in-hospital outcomes, and lower long-term mortality rates compared to nonparticipants, even after propensity-score adjustment. The findings suggest that PMS studies of CAS include a healthier population of patients than those undergoing CAS in routine practice, and that extrapolating results from PMS studies of CAS to larger real world settings may not be appropriate. They also further confirm the importance of large inclusive disease registries with minimal exclusion criteria to properly evaluate the safety and efficacy of newly disseminated technologies in routine practice. See p 1384.
Percutaneous Vascular Stent Implantation as Treatment for Central Vascular Obstruction Due to Fibrosing Mediastinitis
Fibrosing mediastinitis (FM) is a rare but devastating late complication of infection with Histoplasma that manifests as a proliferation of fibrous tissue within the mediastinum, obstructing central vessels and/or airways. In Ϸ20% of affected individuals, bilateral pulmonary arteries, pulmonary veins, and/or airways are affected by the dense fibrous material, which portends an especially grave prognosis. Management of FM is particularly challenging to the clinician. To date, no effective pharmacological or surgical therapy has been shown to provide long-term benefit, and whereas percutaneous interventions using stents to relieve vascular obstruction in FM have been reported in single case reports and small case series, few centers have robust experience with vascular stenting for this disease. This review is the largest published series of percutaneous vascular stenting to ameliorate central vascular obstruction in FM. Our results show that vascular stenting is technically feasible and provides sustained symptomatic relief in the majority of patients. Minor complications, including hemoptysis and catheterization site bleeding, were the most common adverse events, and major complications and/or death after percutaneous intervention were rare. The decision to perform vascular stenting for FM is complex and should be carefully considered after comprehensive radiographic and hemodynamic evaluation and expert consultation to properly select candidates with greatest chance of sustained success. In our experience, percutaneous vascular stenting in selected patients with significant bilateral vascular involvement or superior vena cava syndrome from FM is a good option for relief of clinical symptoms but should be performed at a center experienced in large-vessel stent implantation. See p 1391. than increase thrombosis early after complex interventions and that stent design and deployment drive thrombogenicity. Thinner devices reduce clot formation, whereas coatings are protective, especially in malapposed and overlap scenarios. Indeed, thin polymer-coated devices exhibit low thrombogenicity even in the most complex settings. By defining clot relative to the flow regimes imposed by struts, our models further explain the lack of consensus in clinical trials that sought to correlate deployment and thrombosis. We show here how well-apposed devices create flow separation upstream and downstream of struts and that clot potential tracks with these zones. As struts move off the wall, the flow-separation zones increase and then reduce as flow is restored beneath struts-clotting peaks and falls synchronous with flow alterations. With further displacement, strut-associated disturbances reemerge, eliciting a different pattern of thrombosis. When struts overlap, displaced struts impose a high-risk flow regime, and small changes in strut dimension or stent configuration elicit global changes in flow. Stent thrombosis differs with the nature of flow disruption, and clinical focus on design or deployment alone must give way to a broader context considering their combined impact on flow. Given the inevitable variability in deployment, the choice of optimal design and/or antithrombotic therapies may now be dictated by these patterns of flow disruption. See p 1400.
Association of DASH Diet With Cardiovascular Risk Factors in Youth With Diabetes Mellitus: The SEARCH for Diabetes in Youth Study
Since the publication of the landmark findings of the Dietary Approaches to Stop Hypertension (DASH) trial, the DASH diet has become well known as an effective whole-diet approach to hypertension prevention and blood pressure reduction. However, little is known about its impact on other cardiovascular disease risk factors, especially in youth with type 1 and type 2 diabetes mellitus. In this cross-sectional study, we explored the association of DASH diet with blood lipid levels, lipoproteins, adipocytokines, and measures of adiposity and glycemic control in 2130 youth aged 10 to 22 years with physician-diagnosed diabetes mellitus. Dietary intake was assessed by food frequency questionnaire, categorized into the DASH food groups, and assigned an adherence score. In both type 1 and type 2 diabetes mellitus youth, the average DASH diet scores were low, suggesting very poor dietary intake quality in this population. Of the various cardiovascular disease risk factors evaluated, we found that among youth with type 1 diabetes mellitus, higher adherence to the DASH diet was significantly associated with lower levels of low-density lipoprotein/high-density lipoprotein ratio and A 1c . In youth with type 2 diabetes mellitus, higher adherence to the DASH diet was significantly associated with higher low-density lipoprotein particle density and lower body mass index Z score. In conclusion, the DASH dietary pattern may prove beneficial in the prevention and management of cardiovascular disease risk in this vulnerable population of youth with diabetes mellitus, among whom there is clearly much room for improvement in the quality of dietary intake. See p 1410.
Pathological Healing Response of Explanted MitraClip Devices
Mitral regurgitation remains one of the most common forms of valvular heart disease. Available treatment options have been limited to surgical repair or replacement. However, many patients are elderly, with coexisting conditions that preclude surgery. The MitraClip is a novel percutaneous device that uses a catheter-based system to create a double-orifice mitral valve, thereby reducing mitral regurgitation. The device has been implanted in 337 patients in the Endovascular Valve Edge-to-Edge Repair Study (EVEREST) I and EVEREST II (prerandomization, randomized pivotal study, and high-risk registry) clinical trials for correction of degenerative and functional mitral regurgitation. It was designed to allow removal and conversion to surgery if clinically warranted at any time after device implantation. To date, our laboratory has received 67 explanted devices from 50 patients for pathological analysis. Importantly, this is the first pathological study to report on the gross and histological features observed in the explanted devices at durations of up to 5 years. Analysis of the explants and tissue response provided insights into the time course of healing and documented mechanical stability over time. In addition, the data were stratified between patients with degenerative versus functional mitral regurgitation to elucidate potential differences in healing between these 2 very different disease entities. From the information gleaned from this study, we concluded that factors other than device healing likely explained the persistence or return of mitral regurgitation in this group of explanted patients. Ultimately, the formation of tissue bridge and fibrous capsule around the device may favor long-term durability. See p 1418.
